Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study (CUPID)

Wanwarang Wongcharoen, MD.

Status: Completed

Conditions: Coronary Artery Bypass Grafting

Treatments: Other: Placebo; Dietary Supplement: Curcuminoids

Study type: Interventional

Funder types: Other

Identifiers

NCT01528514

MRG5380258

Details and patient eligibility

About

It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myocardial injury after CABG are lacking. Previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after CABG, compared to placebo.

Enrollment: 200 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients undergoing CABG without valve surgery

Exclusion criteria

• emergency cardiac surgery
• any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization
• patients with cholestatic jaundice (total bilirubin > 2-fold ULN)
• severe liver disease (AST or ALT > 3-fold ULN)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

200 participants in 2 patient groups, including a placebo group

Curcuminoids

Active Comparator group

Treatment:

Dietary Supplement: Curcuminoids

Placebo

Placebo Comparator group

Treatment:

Other: Placebo